SANTA MONICA, CA--(MARKET WIRE)--Feb 9, 2009 -- Cord Blood America, Inc. (OTC BB:
CBAI.OB -
News), the umbilical
cord blood stem cell preservation company (
http://www.cordblood-america.com) focused on bringing the life saving potential of
stem cells to families nationwide and internationally, said today that the Company is now listed on the
ETF Innovators Emerging Stem Cell Index of U.S.-listed stocks. For more information, see the social media news room at
http://www.intelligendo.com.
ETF Innovators, known for creating new global equity indexes with a focus in the healthcare industry, will track the total market value and stock price changes as an indicator of investor and trader sentiment toward the stem cell and regenerative medicine space.
"We are pleased by this recognition. Two thousand and nine has been, so far, both very interesting and positive for stem cell companies, and we're pleased to see this impressive index following our sector," said Matthew Schissler, Founder and CEO of Cord Blood America.
About Cord Blood America
Cord Blood America (OTC BB:CBAI.OB - News) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC BB:CBAI.OB - News), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
